Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorFirst Affiliated Hospital Xi'an Jiaotong University

About this trial

Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proved in reducing IRI in vital organs. This IMPROVE trial plans to enroll 648 patients who are diagnosed with coronary artery disease and are going to take off-pump CABG in five centers in China, to access whether RIC can and improve short-term prognosis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed with coronary artery disease and require off-pump CABG surgery.

Between 18 and 75 years old;

Normal left ventricular systolic function (ejection fraction >40%) and left ventricular end-diastolic internal diameter (<60 mm) in the cardiac ultrasound tests;

No or mild heart valve and great vessel abnormalities which do not require surgical intervention;

Disqualifiers

Severe tissue injuries.

Myalgia, fractures and other peripheral vascular lesions.

Bypass graft being the radial artery.

Stenosis or severe malformations of the subclavian, jugular and femoral arteries and veins.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Remote ischemic conditioning

    Device

    An automatic programmed blood pressure cuffs will be placed on two upper limbs of the patient and pressurized to 200 mmHg (or at least 20 mmHg higher than the systolic blood pressure if the systolic blood pressure of the patient is above 180 mmHg) with 5 minutes of pressurization and 5 minutes of rest. One pressurization with rest is deemed as one cycle (10 minutes), and 4 cycles will be performed each time (for a total of 40 minutes).

Treatment groups

648 Participants
are divided into 2 treatment groups
Group A: RIC groupExperimental treatment 1 intervention
Group B: Control groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

The incidence of MACCE

MACCE includes all-cause of death, myocardial infarction, stroke and coronary revascularization surgery. The data will be obtained at 3-month follow-up, according to medical records of all patients.

Time frame
3-month after the enrollment.

Secondary outcomes

1

The incidence of all-cause of death

The data will be obtained at 3-month follow-up, according to medical records of all patients.

Time frame
3-month after the enrollment.
2

The incidence of myocardial infarction

The data will be obtained at 3-month follow-up, according to medical records of all patients.

Time frame
3-month after the enrollment.
3

The incidence of stroke

The data will be obtained at 3-month follow-up, according to medical records of all patients.

Time frame
3-month after the enrollment.
4

The incidence of coronary revascularization surgery

The data will be obtained at 3-month follow-up, according to medical records of all patients.

Time frame
3-month after the enrollment.

Other outcomes

1

Total costs

Total costs include CABG surgery, medications, examinations, management of complications during the first hospitalization and subsequent hospital admissions for cardiovascular problems. The data will be obtained from medical records and 3-month follow-up.

Time frame
3-month after the enrollment.
2

The incidence of adverse events

Possible adverse events include ischemic pain, tissue damage (such as ulceration, gangrene), headache, bleeding events, neoplasm and accident (such as car accident, suicide) and etc. The data will be recorded from the medical records.

Time frame
3-month after the enrollment.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

First Affiliated Hospital Xi'an Jiaotong University

Lead sponsor

Beijing Anzhen Hospital

Collaborator

People's Hospital of Qinghai Province

Collaborator

The Second Hospital of Yulin City

Collaborator

Baoji Central Hospital

Collaborator